1. Home
  2. CMBM vs LEXX Comparison

CMBM vs LEXX Comparison

Compare CMBM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cambium Networks Corporation

CMBM

Cambium Networks Corporation

HOLD

Current Price

$1.62

Market Cap

65.5M

Sector

Technology

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.59

Market Cap

22.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMBM
LEXX
Founded
2011
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.5M
22.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CMBM
LEXX
Price
$1.62
$0.59
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
1.5M
315.2K
Earning Date
02-19-2026
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$172,215,000.00
$705,923.00
Revenue This Year
N/A
$13.35
Revenue Next Year
$18.01
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.23
$0.66
52 Week High
$6.80
$2.43

Technical Indicators

Market Signals
Indicator
CMBM
LEXX
Relative Strength Index (RSI) 44.11 28.90
Support Level $1.41 $1.05
Resistance Level $1.69 $1.44
Average True Range (ATR) 0.21 0.12
MACD -0.05 -0.06
Stochastic Oscillator 27.45 10.94

Price Performance

Historical Comparison
CMBM
LEXX

About CMBM Cambium Networks Corporation

Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: